Currently, many patients who acquire resistance to EGFR - targeted therapy undergo a tumor biopsy and are designated as either positive or negative for specific secondary mutations. (sciencedaily.com)
We show that H274Y decreases the amount of neuraminidase that reaches the cell surface and that this defect can be counteracted by secondary mutations that also restore viral fitness. (science.sciencemag.org)
Researchers examined tumor samples for various genetic causes of EGFR resistance, including T790M, the most common secondary mutation. (sciencedaily.com)